• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用前列腺特异性膜抗原放射性配体进行前列腺癌的影像学和治疗。

Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.

机构信息

Imaging Department, Imperial College Healthcare NHS Trust, London W6 8RF, United Kingdom.

Division of Biomedical Engineering and Imaging Sciences, Kings College London, London WC2R 2LS, United Kingdom.

出版信息

Br J Radiol. 2024 Aug 1;97(1160):1391-1404. doi: 10.1093/bjr/tqae092.

DOI:10.1093/bjr/tqae092
PMID:38733571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11256943/
Abstract

Prostate specific membrane antigen (PSMA) directed PET imaging has rapidly transformed prostate cancer workup over the past decade and paved the way for a theranostic approach using 177Lu-labelled PSMA radioligand therapy (RLT). This review gives an overview of the underlying principles behind PSMA as a target; the current use of PSMA PET in prostate cancer imaging and benefits compared to conventional imaging; and therapeutic applications including optimisation of patient selection. It also explores the evidence base of PSMA PET for other indications not in routine clinical use and the future of PSMA-directed RLT.

摘要

前列腺特异性膜抗原（PSMA）导向的 PET 成像在过去十年中迅速改变了前列腺癌的检查方式，并为使用 177Lu 标记的 PSMA 放射性配体治疗（RLT）的治疗方法铺平了道路。本文综述了 PSMA 作为靶点的基本原理；目前 PSMA PET 在前列腺癌成像中的应用及其与传统成像相比的优势；以及治疗应用，包括优化患者选择。还探讨了 PSMA PET 在其他非常规临床应用中的适应证的证据基础，以及 PSMA 导向的 RLT 的未来。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/74e48d05ad6a/tqae092f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/c0ee579be2c0/tqae092f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/061d37ce1153/tqae092f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/354bb26b14c2/tqae092f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/8477978691f5/tqae092f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/7a4c3976a06e/tqae092f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/74e48d05ad6a/tqae092f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/c0ee579be2c0/tqae092f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/061d37ce1153/tqae092f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/354bb26b14c2/tqae092f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/8477978691f5/tqae092f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/7a4c3976a06e/tqae092f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/74e48d05ad6a/tqae092f6.jpg

相似文献

1
Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.使用前列腺特异性膜抗原放射性配体进行前列腺癌的影像学和治疗。
Br J Radiol. 2024 Aug 1;97(1160):1391-1404. doi: 10.1093/bjr/tqae092.
2
Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.先进前列腺癌的治疗策略：当前的适应证和未来的发展。
Eur Urol Oncol. 2019 Mar;2(2):152-162. doi: 10.1016/j.euo.2019.01.001. Epub 2019 Jan 31.
3
Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen.前列腺特异性膜抗原放射性配体治疗与正电子发射断层扫描的现状。
Ann Nucl Med. 2020 Dec;34(12):879-883. doi: 10.1007/s12149-020-01549-5. Epub 2020 Nov 11.
4
Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.前列腺特异性膜抗原（PSMA）配体用于前列腺癌的诊断和治疗。
Expert Rev Mol Diagn. 2016 Nov;16(11):1177-1188. doi: 10.1080/14737159.2016.1243057. Epub 2016 Oct 14.
5
Lu-PSMA Radioligand Therapy for Prostate Cancer.镥-PSMA 放射性配体疗法治疗前列腺癌。
J Nucl Med. 2017 Aug;58(8):1196-1200. doi: 10.2967/jnumed.117.191023. Epub 2017 Jun 29.
6
Early treatment response assessment with [Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET.与中期 PSMA-PET 相比，使用[Lu]PSMA 全身闪烁显像进行早期治疗反应评估。
Cancer Imaging. 2024 Sep 19;24(1):126. doi: 10.1186/s40644-024-00773-w.
7
EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT).EANM 程序指南：镥[177Lu]标记的 PSMA 配体（Lu-PSMA-RLT）放射性核素治疗。
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22.
8
Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.前列腺特异性膜抗原PET成像在前列腺癌中的当前应用及未来展望
Q J Nucl Med Mol Imaging. 2019 Mar;63(1):7-18. doi: 10.23736/S1824-4785.18.03059-5. Epub 2018 Mar 8.
9
PSMA radioligand therapy in prostate cancer: overview, latest advances and remaining challenges.前列腺癌中的PSMA放射性配体疗法：概述、最新进展及尚存挑战
Immunotherapy. 2019 Oct;11(15):1267-1271. doi: 10.2217/imt-2019-0146. Epub 2019 Sep 9.
10
Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.探索外照射放疗与[镥]镥-PSMA-617靶向放射性配体疗法联合用于前列腺癌的作用——从实验室到临床应用
Theranostics. 2024 Apr 8;14(6):2560-2572. doi: 10.7150/thno.93249. eCollection 2024.

引用本文的文献

1
Prostate-Specific Membrane Antigen Expression in Colorectal Cancer and Its Potential Implication in Disease Monitoring in Rectal Cancer.前列腺特异性膜抗原在结直肠癌中的表达及其在直肠癌疾病监测中的潜在意义。
J Gastrointest Cancer. 2025 Jul 19;56(1):159. doi: 10.1007/s12029-025-01277-x.
2
PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy.PSMA正电子发射断层显像在接受放射性配体治疗的转移性去势抵抗性前列腺癌患者管理中的应用
Target Oncol. 2025 May 26. doi: 10.1007/s11523-025-01151-7.

本文引用的文献

1
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.EAU-EANM-ESTRO-ESUR-ISUP-SIOG 前列腺癌指南-2024 更新。第一部分：筛查、诊断和以治愈为目的的局部治疗。
Eur Urol. 2024 Aug;86(2):148-163. doi: 10.1016/j.eururo.2024.03.027. Epub 2024 Apr 13.
2
Comparison of F-based PSMA radiotracers with [Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis.F 基 PSMA 放射性示踪剂与 [Ga]Ga-PSMA-11 在前列腺癌 PET/CT 成像中的比较：系统评价和荟萃分析。
Prostate Cancer Prostatic Dis. 2024 Dec;27(4):654-664. doi: 10.1038/s41391-023-00755-2. Epub 2023 Nov 28.
3
Detection of Biochemically Recurrent Prostate Cancer with [F]DCFPyL PET/CT: An Updated Systematic Review and Meta-Analysis with a Focus on Correlations with Serum Prostate-Specific Antigen Parameters.
使用[F]DCFPyL PET/CT 检测生化复发前列腺癌：一项更新的系统评价和荟萃分析，重点关注与血清前列腺特异性抗原参数的相关性。
Tomography. 2023 Aug 15;9(4):1504-1514. doi: 10.3390/tomography9040120.
4
Joint EANM/SNMMI procedure guideline for the use of Lu-labeled PSMA-targeted radioligand-therapy (Lu-PSMA-RLT).EANM/SNMMI 联合实践指南：Lu 标记的 PSMA 靶向放射性配体治疗（Lu-PSMA-RLT）的应用。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2830-2845. doi: 10.1007/s00259-023-06255-8. Epub 2023 May 29.
5
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).前列腺癌分子影像标准化评估框架第二版，包括临床试验的反应评估（PROMISE V2）
Eur Urol. 2023 May;83(5):405-412. doi: 10.1016/j.eururo.2023.02.002. Epub 2023 Mar 17.
6
PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.PSMA 靶向放射性药物在前列腺癌中的应用：现有数据和新试验。
Oncologist. 2023 May 8;28(5):392-401. doi: 10.1093/oncolo/oyac279.
7
Cyclotron Production of Gallium-68 Radiopharmaceuticals Using the Zn(p,n)Ga Reaction and Their Regulatory Aspects.使用锌（p，n）镓反应回旋加速器生产镓-68放射性药物及其监管方面。
Pharmaceutics. 2022 Dec 26;15(1):70. doi: 10.3390/pharmaceutics15010070.
8
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.PSMA PET/CT：前列腺癌成像 2.0 的 EANM 程序指南/ SNMMI 程序标准联合。
Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1466-1486. doi: 10.1007/s00259-022-06089-w. Epub 2023 Jan 5.
9
Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial.回旋加速器生产的68Ga PSMA与发生器生产的68Ga PSMA对比：一项单机构前瞻性临床试验
Transl Oncol. 2023 Feb;28:101593. doi: 10.1016/j.tranon.2022.101593. Epub 2022 Dec 24.
10
Prognostic Value of Tumor Volume Assessment on PSMA PET After Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0.通过PSMA PET/CT共识声明和RECIP 1.0评估的Lu-PSMA放射性配体治疗后PSMA PET上肿瘤体积评估的预后价值
J Nucl Med. 2023 Apr;64(4):605-610. doi: 10.2967/jnumed.122.264489. Epub 2022 Oct 27.